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Despite scientific advances, we are losing ground against Mycobacterium tuberculosis, a pathogen with
which a third of us share our lives. Challenges include fundamental biologic questions; hurdles for transla-
tional medicine; and societal deficits in resources, incentives, collaboration, and leadership. Fortunately,
the crisis is inspiring scientific and organizational creativity.European artists in the 1880s had good
reason to paint remembrances of family
members lost to tuberculosis (TB)
(Figure 1A)—the disease was responsible
for roughly one in four deaths. Hope was
just then beginning to arrive with Robert
Koch’s announcement on March 24, 1882
that TB was caused by a bacillus, Myco-
bacterium tuberculosis (Mtb) (Figure 1B).
After Selman Waksman (Figure 1C) won
a Nobel Prize in 1952 for the discovery of
streptomycin, the first antibiotic effective
against TB, it seemed reasonable for him
to write that ‘‘the complete eradication of
this disease is in sight.’’ Unfortunately,
today’s efforts to slow down the pandemic
are being reduced in some places to
confining patients behind barbed-wire
fences (Figure 1D). How did we fall so far
short of what Waksman thought we were
about to achieve? How much will the 21st
century resemble the 19th in our relation-
ship with TB? This commentary marks
World TB Day (observed on March 24) by
sizing up shortcomings in scientific under-
standing and public policy, the two legs on
which we need to run if we are to outpace
pandemic TB.
SizingUp theThreat:WhichWayAre
We Heading?
Mtb has no other known host but humans.
Thus, in theory, we could exterminate it,
eliminating the world’s third leading cause
of premature human death. However, to
put this notion into perspective, consider
that one-third of us are latently infected
with Mtb, often for life, and this is the
situation after perhaps 500,000 years of
coevolution (Sizemore and Heilman,
2008). Thus, humans and Mtb have long220 Cell Host & Microbe 5, March 19, 2009 ªexisted in a metastable equilibrium in
which neither has found or taken the
opportunity to eliminate the other. Today,
the long-standing balance between hu-
mans and Mtb appears to be shifting.
While one might expect this to mean that
science and technology have finally put
humans in a position to control TB, funda-
mental forces threaten to drive the rela-
tionship in the other direction.
In the distant past, small, scattered
human populations probably imposed
a selection pressure for coevolution of
persistent pathogens that inflicted low
mortality after a latent period long enough
to allow the birth of new hosts (Blaser and
Kirschner, 2007). Inpresent times,however,
the enormous expansion of the human
population in size and mobility is likely to
support Mtb’s adaptation to a higher level
of virulence (Blaser and Kirschner, 2007).
Because Mtb is an airborne pathogen,
ease of transmission is further favored by
the number of settings where infected
people share air with uninfected people,
such as in airplanes, clinics, and prisons.
The incidence of TB began to fall in industri-
alizing regions coincident with improve-
ments in sanitation and housing, but such
improvements are lacking in many of the
world’s population centers. Thus, it may
never in human history have been so easy
for Mtb to spread. Ease of spread reduces
‘‘purifying selection,’’ the penalty paid by
the pathogen for the fitness costs of muta-
tion. In fact, there is evidence of increasing
genetic drift in Mtb, which could accelerate
the emergence of spontaneous drug resis-
tance (Hershberg et al., 2008).
Pandemic immunodeficiency is another
new force in human history. In an indi-2009 Elsevier Inc.vidual with latent TB infection, coinfection
with HIV increases the risk of developing
active TB from about 5%—10% per life-
time to about 10% per year. Moreover,
TB becomes harder to diagnose and treat
in immunodeficient hosts.
Also new to human history is a pandemic
of obesity, which is driving a pandemic of
type 2 diabetes (Nathan, 2008). Like HIV,
but for unknown reasons, diabetes
increases the incidence of active TB and
prolongs the time to cure. In some coun-
tries, the excess proportion of TB cases
attributable to diabetes is greater than to
HIV/AIDS (Nathan, 2008). Insufficient
intake of protein and calories also predis-
poses to the conversion of latentMtb infec-
tion to active TB. Thus, the equilibrium
between Mtb and humans that evolved at
a given mean level of energy balance
appears to be disturbed at both higher
and lower levels.
The medicine chest stocked against TB
in the mid-20th century has nearly emptied
in the early 21st century as the retreat of
much of the pharmaceutical industry
from antibiotic research and development
coincides with the rapid spread of drug
resistance in Mtb (Nathan, 2004).
What drives the spread of drug resis-
tance? One factor is that high drug prices
create an opportunity to profit from illicit
distribution of diluted medicines; ineffec-
tive doses select for drug-resistant strains.
Another factor is failure to employ effective
combination chemotherapy, particularly in
cases where the two main drugs, isoniazid
and rifampin, are prescribed, but the
infecting strain is already resistant to one
of them. This promotes selection for
resistance to the other, creating
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TB. The situation is difficult to
avoid, since drug suscepti-
bility testing (DST) is used in
only 3% of cases in high-
burden countries (Young
et al., 2008).
NIH leaders recently
concluded that ‘‘. current
global control strategies are
not sufficient to significantly
affect TB rates worldwide’’ (Si-
zemore and Heilman, 2008). It
seems likely that we will only
be able to alter this situation
with diagnostics, vaccines,
and drugs whose develop-
ment will require deeper scien-
tific understanding.
Back to Basics:
Challenges for
Fundamental and
Translational Research
Challenges for Basic
Research
What is the fundamental
nature of the host-pathogen
relationship in TB? Textbooks
teach that bacteria in the
human body are invaders
that the immune system
destroys. A new view holds
that a human being is a poly-
phyletic consortium. Thousands of
prokaryotes that cohabit at our epithelial
surfaces contribute many of our metabo-
lites, cue our immune system to develop,
help us avoid infectious disease, induce
tolerance to themselves, and perhaps
help tolerize us to what we eat. Pathogenic
microbes are a minority, even when the
host’s immune system is compromised
and certain otherwise harmless microbes
become opportunistic pathogens. These
concepts of host-microbe relationships
do not describe the relationships humans
have with Mtb. Mtb does not dwell on
our epidermal and mucosal surfaces but
deep in our tissues, mostly inside our cells.
Mtb may provide beneficial immune
stimulation to most of those infected,
helping to prevent infectious and allergic
diseases, yet grievously harms a small
proportion (albeit a huge number), most
of whom have normal immunity. In short,
Mtb can be at the same time a beneficial
commensal, deep invader, opportunistic
pathogen, and killer of the otherwise
well. Even though healthy immune
systems react strongly to Mtb, in most of
those infected, viable Mtb persists for
life. We do not understand the forces
that shape this kind of host-pathogen rela-
tionship.
We know a great deal about how
dendritic cells prepare T cells to instruct
macrophages to kill Mtb, but relatively
little about the chemistry that macro-
phages use to do so and why they often
fail. Until we know which biochemical
mechanisms are involved, we can’t
predict what pathways Mtb uses to resist
elimination—and those pathways, too,
become harder to target with chemother-
apeutics. Part of the problem is that our
in vitro techniques do not adequately
recapitulate the differentiation of human
monocytes to tissue macrophages. It is
a major obstacle to TB research that
in vitro-derived human macrophages
permit Mtb to replicate to a variable
extent, but do not kill it, while in vivo,
human macrophages apparently kill most
Mtb in most infected people,
even if they fail to achieve
eradication.
By what mechanisms does
diabetes constitute a state of
immunodeficiency toward
Mtb? It has not even been
articulated as a problem that
diabetes may be on the way
to becoming one of the com-
monest immunodeficiency
states.
What are the metabolic
states of Mtb in the heteroge-
neous environments that it
occupies in man (Nathan
et al., 2008)? Can we develop
comprehensive metabolomic
profiles of Mtb in vitro under
conditions that replicate those
in vivo? Until we know what
metabolic pathways Mtb
relies on to persist, we may
be confined to empirical
approaches to targeting such
pathways.
What governs Mtb’s cell
cycle? What drives the
organism into and out of non-
replicative persistence?
What genes in Mtb are essen-
tial for these responses?
Why does Mtb have no
other known natural host but
humans? Like the closely relatedM. bovis,
Mtb can infect many species, but in
striking contrast to M. bovis, Mtb is
naturally transmitted only to and by hu-
mans. Host defense is a composite of
resistance and ‘‘tolerance,’’ where ‘‘toler-
ance’’ refers to avoidance of pathology.
Infectious disease pathology is path-
ogen-induced but often substantially
host-mediated (Schneider and Ayres,
2008). The ‘‘tolerant’’ patient who
succumbs rapidly to systemic TB without
breakdown of infected pulmonary tissue
into an airway is not contagious; if all
people were ‘‘tolerant’’ in this way, Mtb
would go extinct. Instead, for its transmis-
sion, Mtb requires a specific form of
host ‘‘intolerance’’: liquefaction of lung
with erosion into a bronchus. Thus, the
precise form of human ‘‘intolerance’’
may dictate Mtb’s host range. What
factors regulate the timing, extent, and
nature of human ‘‘intolerance’’ to Mtb,
and how can this be studied in animals
that lack it?
Figure 1. TB Control: Cycling Back to the 19th Century?
(A) ‘‘Det Syke Barn’’ (The Sick Child) by Edvard Munch, 1885, depicts the
artist’s sister dying of tuberculosis. (Copyright Tate, London 2009).
(B) Robert Koch announced the cause of tuberculosis in 1882, for which he
won a Nobel Prize in 1905.
(C) Selman A. Waksman discovered streptomycin, the first drug effective
against TB, for which he won a Nobel Prize in 1952. The quotation in the text
is from The Conquest of Tuberculosis (Waksman, S.A. [1964]. Berkeley:
University of California Press).
(D) Incarcerated patients with MDR TB repeatedly escaped the quarantine
facility shown here in Port Elizabeth, South Africa, as reported by C.W. Dugger
in the New York Times (March 25, 2008). (Mariella Furrer/The New York Times/
Redux).
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What can we do at the point of care in
resource-poor settings to make a prompt,
accurate diagnosis of TB, distinguish
latent from active infection and identify
patterns of drug sensitivity and resis-
tance? Mark Harrington, head of the
Treatment Action Group, expresses
a widely felt frustration that we are still
relying on sputum smear microscopy for
diagnosis of pulmonary TB, though it
often fails, along with culture results
that often reach the point of care many
months after treatment decisions were
made (M. Harrington, personal communi-
cation).
What biomarkers can distinguish prior
cured infection, latent infection, and early
disease (Young et al., 2008) and allow
the monitoring of clinical trials of drugs
and vaccines (Fauci, 2008)? How can we
design vaccines for man based on exper-
iments in mice whose endpoints are
reductions in Mtb colony-forming units,
when such interventions do not protect
the mice from dying of TB?
How is it that Mtb provides what are
among the strongest known antigens and
adjuvants for humans, elicits robust
humoral and cell-mediated immunity,
and protects against infection by diverse
heterologous organisms, yet confers no
protection against infection by itself
(Young et al., 2008)? Why does BCG, the
most widely used vaccine in the world,
protect children in some countries but
not others and fail to protect most adults?
Would a vaccine protect if it sped up the
sluggish appearance of Mtb antigen-
specific T cells in the lungs upon Mtb
infection (Gallegos et al., 2008; Wolf
et al., 2008)? Given that activated macro-
phages appear to face an intrinsic limit in
their ability to control Mtb (Jung et al.,
2005), will it be fruitful to design TB
vaccines for immunocompetent hosts
with the goal of driving higher production
of Mtb-elicited interferon-g production
than occurs with natural exposure? Is it
possible that TB could be most effectively
prevented in latently infected populations
not with either a vaccine or drugs, but
with both together, perhaps using drugs
that allow the activated macrophage to
overcome its limitations?
How can we markedly improve the likeli-
hood, now considered remote, of intro-
ducing more than one new drug for TB in222 Cell Host & Microbe 5, March 19, 2009 ªthe next 5 years? As noted by Thomas
Dick at the Novartis Institute of Tropical
Disease Research, one of the few indus-
trial groups developing new TB drugs,
our present methods for target validation
and compound screening are poor predic-
tors of clinical efficacy (T. Dick, personal
communication).
Given that most people infected with
Mtb succeed in controlling the infection
for a lifetime, and given that the conditions
encountered by Mtb in the host differ
drastically from those encountered by
Mtb in vitro in standard culture medium,
shouldn’t we take the in vivo environment
into account as we seek new chemother-
apeutics? Table 1 lists some of the
diverse relationships that exist between
anti-infectives and host immunity. Can
we design new chemotherapeutics that
cooperate with, rather than are antago-
nized by, host factors that help control
Mtb?
The Ball in Society’s Court:
Challenges for Public Policy
Resources
The past decade has seen a major influx
of resources for TB research, mostly
from NIH, the Bill and Melinda Gates
Foundation, and the European Union.
Nonetheless, resources remain insuffi-
cient to achieve control. In the words of
Peter Small (Senior Program Officer, TB,
Global Health Program, Bill and Melinda
Gates Foundation), ‘‘Unfortunately,
everything is more difficult, expensive,
and time consuming than we had hoped’’
(P. Small, personal communication).
Melvin Spigelman (CEO of the Global
Alliance for TB Drug Development) notes
that there is a ‘‘glaring need for more
resources to have a good shot at being
successful. Resource needs grow almost
exponentially as projects progress’’ (M.
Spigelman, personal communication).
The Treatment Action Group estimates
that worldwide TB research and develop-
ment has reached $429 million per year,
but that this is at least 4-fold lower than
the need. At about $160 million/year, the
NIH budget for TB research is less than
for anthrax or smallpox and about one-
twentieth the funding for research on
HIV/AIDS (M. Harrington, personal
communication).
Incentives
Another obstacle to control of TB is the
way we apply patents to reward the devel-2009 Elsevier Inc.opment of drugs and vaccines, namely, to
protect a monopoly that allows pricing to
maximize profit. As long as this remains
the only option for businesses to compete
successfully in financial terms, they are
exceedingly unlikely to be able to consis-
tently and substantially fulfill their desire
to develop and distribute drugs and
vaccines to people who are too poor to
pay for them. The problem could be
resolved with a global, governmentally
financed Health Impact Fund to which
patent holders could voluntarily apply for
monetary rewards proportional to a given
product’s impact on the global burden of
disease (Pogge, 2008). Practical issues
can be solved (Pogge, 2008), and funding
is feasible, in part through reduced
government costs for regulation of drug
prices, purchase of drugs, and subsidy
of citizens’ drug purchases. A fitting way
to finance activities of such high social
value is through a tiny tax on an enormous
economic activity of little social value—
the short-term trading of stocks, futures,
and currencies (Stiglitz, 1989)—and on
the movement of multinational corpora-
tions’ profits among national currencies
(Tobin, 1978).
Collaborations
As Peter Small notes, ‘‘There is an
urgent need for innovation at all aspects
of the complex system that provides
care for TB patients’’ (P. Small, personal
communication). One critical innovation
will be for academia and industry to
collaborate in new ways. Currently,
academics try to fill a void by acting
as product developers (Sizemore and
Heilman, 2008). This has not worked
well. Academics tend to be adept at
innovation but not at developing prod-
ucts. The idea that academics can begin
the process and industry can finish it
has not worked well, either. If industry
waits for academics to initiate drug
development, the pharmaceutical quality
of the compounds is often too poor to
lead to success. Not only do both
sectors need to collaborate, but they
need to do so from the outset (Nathan,
2004).
Fortunately, the situation may be start-
ing to change. The Bill and Melinda Gates
Foundation has funded programs that
support public-private partnerships for
TB diagnostics (FIND), vaccines (AERAS),
and drug development (Global Alliance).
Eli Lilly, Inc. and the Infectious Disease
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Relationship Example for Mtb
Compound is administered without regard to its interactions
with the host environment
All drugs in clinical use
Compound’s ability to achieve stable cure is impaired
by immunosuppression, suggesting that cure depends
on actions of the compound plus those of immunity.
Where a biochemical mechanism was studied, expression
of iNOS was required for stable cure.
Mechanism unknown: Many compounds2 Mechanism studied:
isoniazid + pyrazinamide (J. McKinney, J. MacMicking, C.N.,
B. Bloom, and W. Jacobs, Jr., unpublished data)
Compound’s efficacy is antagonized by host’s immune
response.
Isoniazid (B. Gold, K. Rhee, D. Vargas, F. Isovski, J. Roberts,
L.P.S. de Carvalho, and C.N., unpublished data)
Compound targets a microbial molecule that the pathogen needs
to resist host immunity and metabolic constraints.
Inhibitors of Mtb’s dihydrolipoamide acyltransferase3
Compound generates or mimics an element of host immune
chemistry.
Certain nitroimidazoles4
Compound targets the same microbial molecules
as host immune chemistry, but is structurally different
from the host-derived product, so that the pathogen lacks
pathways to detoxify it.
Diarylquinoline targeting Mtb’s ATP synthase5,6
Compound targets a host molecule that the pathogen depends
on to cause disease.
Inhibitors of host protein kinase B7
Compound targets a host pathway that contributes to pathology. Thalidomide (reduces host cytokine production, but effects
may be clinically adverse)8
1 ‘‘Interactions between chemotherapy and the host environment’’ refers to interactions that affect the bacterium, not those that affect the drug, such
as its catabolism or excretion. ‘‘Host environment’’ means conditions that impose metabolic constraints on the pathogen, including host immunity.
2 McCune, R.M., Feldmann, F.M., and McDermott, W. (1966). Microbial persistence. II. J Exp Med 123, 469–486.
3 Bryk, R., Gold, B., Venugopal, A., Singh, J., Samy,R., Pupek, K., Cao, H., Popescu, C., Gurney, M., Hotha, S., et al. (2008). Cell Host Microbe3, 137–145.
4 Singh, R., Manjunatha, U., Boshoff, H.I., Ha, Y.H., Niyomrattanakit, P., Ledwidge, R., Dowd, C.S., Lee, I.Y., Kim, P., Zhang, L., et al. (2008). Science
322, 1392–1395.
5 Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005).
Science 307, 223–227.
6 Rhee, K.Y., Erdjument-Bromage, H., Tempst, P., and Nathan, C.F. (2005). Proc. Natl. Acad. Sci. U.S.A. 102, 467–472.
7 Kuijl, C., Savage, N.D., Marsman, M., Tuin, A.W., Janssen, L., Egan, D.A., Ketema, M., van den Nieuwendijk, R., van den Eeden, S.J., Geluk, A., et al.
(2007). Nature 450, 725–730.
8 Schoeman, J.F., Springer, P., van Rensburg, A.J., Swanevelder, S., Hanekom, W.A., Haslett, P.A., and Kaplan, G. (2004). J. Child Neurol. 19,
250–257.Research Institute in Seattle are launching
the Lilly TB Drug Discovery Initiative
(http://www.newtbrx.org) with in-kind
support from NIH and Academia Sinica
(Taiwan). Sanofi-Aventis is considering
collaborations with academic scientists
for early-stage TB drug development.
Thus, ‘‘This changed research environ-
ment may signal the time to refocus
academic research activities on areas
where they are needed most: developing
enabling technologies, characterizing
biochemical processes that create
assays and tools for product devel-
opers. and answering critical questions
in clinical TB that have arisen as new
candidate products have entered human
testing’’ (Sizemore and Heilman, 2008).
Leadership
Both the public and private sectors need
to take up the leadership that the philan-
thropic sector cannot adequately or indef-initely provide. Strong public leadership is
needed in donor nations, nations with
high TB burdens, institutions of interna-
tional affairs, ministries of health, and
local communities. The pharmaceutical
industry needs to take a leadership role
as well, by helping society create
a sustainable business model for the full-
scale, ongoing research, development,
distribution, and monitoring of vaccines,
anti-infectives, and other medicines that
meet the needs of people whose
economic means are severely limited.
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